A Phase 3, Double-blinded, Randomized, Comparator Trial of the Safety and Efficacy of a Single Dose of Dalbavancin to Twice Daily Linezolid for the Treatment of Community Acquired Bacterial Pneumonia

Trial Profile

A Phase 3, Double-blinded, Randomized, Comparator Trial of the Safety and Efficacy of a Single Dose of Dalbavancin to Twice Daily Linezolid for the Treatment of Community Acquired Bacterial Pneumonia

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs Dalbavancin (Primary) ; Azithromycin; Linezolid; Linezolid
  • Indications Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors Durata Therapeutics
  • Most Recent Events

    • 21 Jan 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 21 Jan 2016 Planned primary completion date changed from 1 May 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
    • 21 Jan 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top